1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
iXensor Co., Ltd.

iXensor Co., Ltd.

TTPEX:6734
5.85
TWD
+0.74
(+14.48%)
277.87MMarket Cap
iXensor Co., Ltd.
TPEX:6734
(Taipei Exchange)

Recent

price

5.85

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
0.02
0.82
0.58
1.44
0.76
1.11
4.54
0.89
0.8
0.78
- -
Revenue per Share
-7.31
-6.08
-5.47
-5.03
-3.63
-3.27
-0.21
-2.69
-1.92
-1.37
- -
Basic EPS, GAAP
-7.81
-7.06
-5.69
-4.82
-2.8
-3.29
0.32
-2.04
-1.71
-1.09
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
7.04
11.44
7.3
3.74
2.54
3.44
1.4
0.31
0.57
0.21
Book Value per Share
- -
6.91
11.31
7.1
3.56
2.12
3.07
1.06
0.09
0.41
0.06
Tangible Book Value per Share
13
18
20
21
21
22
23
23
24
34
41
Basic Weighted Avg Shares
- -
15
11
30
16
25
105
21
19
27
- -
Sales/Revenue/Turnover
-42,229.48
-743.77
-951.58
-362.02
-494.94
-328.81
-4.97
-301.77
-236.82
-170.06
- -
Operating Margin (%)
6
7
8
12
11
9
7
6
6
6
- -
Depreciation Expense
-95
-108
-108
-105
-77
-73
-5
-63
-47
-47
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-37,833.47
-736.76
-940.59
-348.47
-481.12
-294.75
-4.65
-302.51
-240.55
-174.69
- -
Profit Margin (%)
- -
116
211
122
52
40
64
31
28
20
5
Working Capital
- -
- -
- -
6
2
- -
13
25
18
12
8
LT Debt
- -
148
241
154
79
57
81
33
10
23
9
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-145.75
-55.61
-53.1
-65.86
-107.4
-7.11
-111.43
-218.81
-283.37
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
20
25
20
LT Borrowings
7
10
8
LT Finance Leases
3
2
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
33
41
42
Market Capitalization
211
237
278

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
27
55
35
Cash, Cash Equivalents & STI
15
41
21
Accounts Receivable, Net
- -
- -
1
Inventories
5
9
8
Total Current Liabilities
51
34
30
Payables & Accruals
- -
- -
- -
ST Debt
20
25
20
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
2.93%
129.72%
Free Cash Flow
- -
-171.87%
-10.66%
Net Income, GAAP
- -
213.64%
0.32%
Sales/Revenue/Turnover
- -
66.26%
38.14%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
19
2025
- -
- -
27
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-1.92
2025
- -
- -
-1.37
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
iXensor Co., Ltd. (6734.TWO) develops smartphone-based diagnostic platforms that transform ordinary mobile devices into lab-grade in vitro diagnostic tools for point-of-care and at-home testing using its proprietary PixoTech platform protected by over 80 international patents; core products include the PixoTest Blood Glucose Monitoring System, the world's first US FDA-approved smartphone camera-based blood glucose test launched in 2017, PixoTest POCT System for HbA1c and lipid panel analysis in chronic disease management, Eveline Smart Fertility System and Eveline Care Telehealth Platform for women's health including ovulation and hormone tracking, and PixoTest COVID-19 Rapid Antigen Test for infectious diseases with confirmed detection of variants like Omicron; additional offerings encompass PixoHealth Pass Admin app and web portal for data management, alongside biochemical tests for total cholesterol, triglycerides, and cardiovascular markers. Founded in 2012 in Silicon Valley and incorporated in Taipei, Taiwan, where it maintains headquarters at 6F., No. 9, Aly. 2, Ln. 35, Jihu Rd., Neihu Dist., the company operates primarily in the medical devices and digital health sectors, targeting consumers, clinics, and healthcare providers globally with a focus on chronic diseases, women's health, and infectious diseases; it serves markets in Asia, Europe, and emerging regions including Africa through partnerships. Recent developments include receipt of the Taiwan Excellence Award 2025 for its PixoTest Vision Analysis System (Lipid) in late 2024, ongoing expansion of PixoTech platform-as-a-service licensing as a key growth driver, a strategic partnership with Ilara Health announced around 2023 to deliver PixoTest POCT for diabetes and hyperlipidemia testing in Kenyan primary care facilities with data integration into the Mbali Health platform, and earlier alliances such as the 2022 strategic investment and technology licensing deal with Rohto Pharmaceutical for self-testing products in women's health and infectious diseases in Japan, plus a partnership with Innova Medical Group for rapid diagnostics scaling.